The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Impact of gemcitabine (Gem)- or capecitabine (Cape)-based chemoradiation (CRT) on health-related quality of life (HRQL) in patients with locally advanced pancreatic cancer (LAPC): Outcomes from the randomized phase II SCALOP trial.
Somnath Mukherjee
No relevant relationships to disclose
Chris Hurt
No relevant relationships to disclose
Peter Dutton
No relevant relationships to disclose
John A. Bridgewater
No relevant relationships to disclose
Thomas Crosby
No relevant relationships to disclose
Alec Mcdonald
No relevant relationships to disclose
Stephen Falk
No relevant relationships to disclose
Ross A. Abrams
No relevant relationships to disclose
Tim Maughan
No relevant relationships to disclose
Gareth Griffiths
No relevant relationships to disclose